Postdoctoral Fellow - Systems Biology - Chen Laboratory
- City of Hope
- Location: Monrovia, CA
- Job Number: 7073503 (Ref #: 10007682rxv_117_1)
- Posting Date: Dec 24, 2020
- Application Deadline: Open Until Filled
Job DescriptionAbout City of Hope
City of Hope, an innovative biomedical research, treatment and educational institution with over 6,000 employees, is dedicated to the prevention and cure of cancer and other life-threatening diseases and guided by a compassionate, patient-centered philosophy.
Founded in 1913 and headquartered in Duarte, California, City of Hope is a remarkable non-profit institution, where compassion and advanced care go hand-in-hand with excellence in clinical and scientific research. City of Hope is a National Cancer Institute designated Comprehensive Cancer Center and a founding member of the National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers that develops and institutes standards of care for cancer treatment.
Dr. Chun-Wei David Chen’s laboratory in Systems Biology - City of Hope is looking for a talented Postdoctoral Fellow for cancer research. This laboratory is skilled in high-throughput CRISPR genetic screens, next-generation sequencing (NGS), epigenomic/transcriptomic analyses (ChIPseq, ATACseq, RNAseq, etc.), structural genetics, and compound screens. They also involve in technology development including CRISPR gene body scan and single-cell CRISPR screens (10X Genomics). Dr. Chen’s research program is supported by several NIH (R37, R01s, U54, K99/R00) and foundation (ASH, LLS, ALSF, SU2C) awards.
Key Responsibilities include:
- Expected to carry out projects in ovarian cancer research, including but not limited to identifying mechanisms underlying therapy resistance.
- The therapy resistance mechanisms both within tumor cells and tumor-associated immune cells will be investigated.
- Will also contribute to development of novel therapies.
Basic education, experience and skills required for consideration:
- A Ph.D. degree in biomedical sciences, structural biology, computational biology or bioinformatics.
- Good oral and written communication skills in English.
- Experience in cell biology, molecular cloning or animal model studies.
- Experience in transcriptomic, proteomic, epigenetic, molecular dynamic, or protein structural data analysis.
- Experience in protein purification, compound screen, protein/protein or protein/compound interaction.
- Experience in R, Python, Perl, UNIX/LINUX, etc.
- Please submit a brief motivation statement/cover letter, CV and a list of three references with your application.
- For more information on Dr. David Che’s research, please click here.
- Recent publications:
- C.W. Chen, R. Koche, A. Sinha, A. Deshpande, N. Zhu, R. Eng, J. Doench, H. Xu, S. Chu, J. Qi, X. Wang, C. Delaney, K.M. Bernt, D.E. Root, W.C. Hahn, J.E. Bradner, S.A. Armstrong. DOT1L Inhibits SIRT1-mediated Epigenetic Silencing to Maintain Leukemic Gene Expression in MLL-rearranged Leukemia. Nature Medicine. 2015, 21; 335-343.
- H Xu, D.G. Valerio, M.E. Eisold, A. Sinha, R.P. Koche, W. Hu, C.W. Chen, S.H. Chu, G.L. Brien, J.J. Hsieh, P. Ernst, S.A. Armstrong. NUP98-fusion Proteins Interact with the NSL and MLL1 Complexes to Drive Leukemogenesis. Cancer Cell. 2016; 30(6):863-878.
- M.W. Kühn, E. Song, Z. Feng, A. Sinha, C.W. Chen, A.J. Deshpande, M. Cusan, N. Farnoud, A. Mupo, C. Grove, R. Koche, J.E. Bradner, E. de Stanchina, G.S. Vassiliou, T. Hoshii, S.A. Armstrong. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. Cancer Discovery. 2016; 6(10):1166-1181.
- N. Zhu, M. Chen, R. Eng, J. DeJong, A.U. Sinha, N.F. Rahnamay, R. Koche, F. Al-Shahrour, J.C. Minehart, C.W. Chen, A.J. Deshpande, H. Xu, S.H. Chu, B.L. Ebert, R.G. Roeder, S.A. Armstrong. MLL-AF9- and HOXA9-mediated Acute Myeloid Leukemia Stem Cell Self-renewal Requires JMJD1C. Journal of Clinical Investigation. 2016, 126(3):997-1011.
- S.C.W. Lee, H. Dvinge, E. Kim, H. Cho, J.B Micol, Y.R. Chung, B.H. Durham, A. Yoshimi, Y.J. Kim, M. Thomas, C. Lobry, C.W. Chen, A. Pastore, J. Taylor, X. Wang, A. Krivtsov, S.A. Armstrong, J. Palacino, S. Buonamici, P.G. Smith, R.K. Bradley, O. Abdel-Wahab. Modulation of Splicing Catalysis for Therapeutic Targeting of Leukemias with Spliceosomal Mutations. Nature Medicine. 2016; 22(6):672-8.
- D.G. Valerio, H. Xu, C.W. Chen, T. Hoshii, M.E. Eisold, C. Delaney, M. Cusan, A.J. Deshpande, C.H. Huang, A. Lujambio, Y.G. Zheng, J. Zuber, T.K. Pandita, S.W. Lowe, S.A. Armstrong. Histone Acetyltransferase Activity of MOF Is Required for MLL-AF9 Leukemogenesis. Cancer Research. 2017; 77(7):1753-1762.
- S.P. Wang, Z. Tang, C.W. Chen, M. Shimada, R.P. Koche, L.H. Wang, T. Nakadai, A. Chramiec, A.V. Krivtsov, S.A. Armstrong, R.G. Roeder. A UTX-MLL4-p300 Transcriptional Regulatory Network Coordinately Shapes Active Enhancer Landscapes for Eliciting Transcription. Molecular Cell. 2017; 67(2):308-321.
- T. Hoshii, P. Cifani, Z. Feng, C.H. Huang, R. Koche, C.W. Chen, C.D. Delaney, S.W. Lowe, A. Kentsis, S.A. Armstrong. A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response. Cell. 2018; 172(5):1007-1021.e17
- A.K.N. Chan, C.W. Chen. Rewiring the Epigenetic Networks in MLL-Rearranged Leukemias: Epigenetic Dysregulation and Pharmacological Interventions. Front Cell Dev Biol. 2019; 7:81.
- He X, Zhu Y, Lin YC, Li M, Du J, Dong H, Sun J, Zhu L, Wang H, Ding Z, Zhang L, Zhang L, Zhao D, Wang Z, Wu H, Zhang H, Jiang W, Xu Y, Jin J, Shen Y, Perry J, Zhao X, Zhang B, Liu S, Xue SL, Shen B, Chen CW, Chen J, Khaled S, Kuo YH, Marcucci G, Luo Y, Li L. PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD(+) acute myeloid leukemia. Blood. 2019; 134(6):548-560.
- Hurtz C, Chan LN, Geng H, Ballabio E, Xiao G, Deb G, Khoury H, C.W. Chen, Armstrong SA, Chen J, Ernst P, Melnick A, Milne T, Müschen M. Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia. Genes Dev. 2019; 33(17-18):1265-1279.
- Zhu Y, He X, Lin YC, Dong H, Zhang L, Chen X, Wang Z, Shen Y, Li M, Wang H, Sun J, Nguyen LX, Zhang H, Jiang W, Yang Y, Chen J, Müschen M, C.W. Chen, Konopleva MY, Sun W, Jin J, Carlesso N, Marcucci G, Luo Y, Li L. Targeting PRMT1-Mediated FLT3 Methylation Disrupts Maintenance of MLL-rearranged Acute Lymphoblastic Leukemia. Blood. 2019.
- Qin H, Dong Z, Wang X, Cheng WA, Wen F, Xue W, Sun H, Walter M, Wei G, Smith DL, Sun X, Fei F, Xie J, Panagopoulou TI, C.W. Chen, Song JY, Aldoss I, Kayembe C, Sarno L, Müschen M, Inghirami GG, Forman SJ, Kwak LW. CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. Science Translational Medicine. 2019 Sep 25;11(511).
- Shen C, Sheng Y, Zhu AC, Robinson S, Jiang X, Dong L, Chen H, Su R, Yin Z, Li W, Deng X, Chen Y, Hu YC, Weng H, Huang H, Prince E, Cogle CR, Sun M, Zhang B, C.W. Chen, Marcucci G, He C, Qian Z, Chen J. RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia. Cell Stem Cell. 2020. 27:1-17.
- Dzama MM, Steiner M, Rausch J, Sasca D, Schönfeld J, Kunz K, Taubert MC, McGeehan GM, C.W. Chen, Mupo A, Hähnel PS, Theobald M, Kindler T, Koche RP, Vassiliou GS, Armstrong SA, Kühn MWM. Synergistic Targeting of FLT3 Mutations in AML via Combined Menin-MLL and FLT3 Inhibition. Blood. 2020 Jun 26:blood.2020005037. doi: 10.1182/blood.2020005037.
- Q. Liu, M. Garcia, S. Wang, and C.W. Chen. Therapeutic Target Discovery Using High-Throughput Genetic Screens in Acute Myeloid Leukemia. Cells. 2020, 9(8), 1888.
- Cai SF, Chu SH, Goldberg AD, Parvin S, Koche RP, Glass JL, Stein EM, Tallman MS, Sen F, Famulare CA, Cusan M, Huang CH, C.W. Chen, Zou L, Cordner KB, DelGaudio NL, Durani V, Kini M, Rex M, Tian HS, Zuber J, Baslan T, Lowe SW, Rienhoff HY, Letai A, Levine RL, Armstrong SA. Leukemia cell of origin influences apoptotic priming and sensitivity to LSD1 inhibition. Cancer Discovery. 2020 Jun 30:CD-19-1469.
- Chan LN, Murakami MA, Robinson ME, Caeser R, Sadras T, Lee J, Cosgun KN, Kume K, Khairnar V, Xiao G, Ahmed MA, Aghania E, Deb G, Hurtz C, Shojaee S, Hong C, Pölönen P, Nix MA, Chen Z, C.W. Chen, Chen J, Vogt A, Heinäniemi M, Lohi O, Wiita AP, Izraeli S, Geng H, Weinstock DM, Müschen M. Signalling input from divergent pathways subverts B cell transformation. Nature. 2020 Jul;583(7818):845-851.
- 2020-05-21 DF/HCC, Harvard Medical School CRISPR gene body scan – merging functional genomics, structural biology, and drug discovery
City of Hope is a community of people characterized by our diversity of thought, background and approach, but tied together by our commitment to care for and cure those with cancer and other life-threatening diseases. The innovation that our diversity produces in the areas of research, treatment, philanthropy and education has made us national leaders in this fight. Our unique and diverse workforce provides us the ability to understand our patients' needs, deliver compassionate care and continue the quest for a cure for life-threatening diseases. At City of Hope, diversity and inclusion is a core value at the heart of our mission. We strive to create an inclusive workplace environment that engages all of our employees and provides them with opportunities to develop and grow, both personally and professionally. Each day brings an opportunity to strengthen our work, leverage our different perspectives and improve our patients’ experiences by learning from others. Diversity and inclusion is about much more than policies and campaigns. It is an integral part of who we are as an institution, how we operate and how we see our future.